HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 293/1/F52    most recent 00119.2007v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Yu, F. Articles by Price, P. M. Search for Related Content PubMed PubMed Citation Articles by Yu, F. Articles by Price, P. M.

EDITORIAL FOCUS

Involvement of the CDK2-E2F1 pathway in cisplatin cytotoxicity in vitro and in vivo

Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas

Submitted 9 March 2007 ; accepted in final form 18 April 2007

E2F1 is a key regulator that links cell cycle progression and cell death. E2F1 activity is controlled by Cdk2-cyclin complexes via several mechanisms, such as phosphorylation of retinoblastoma protein (pRb) to release E2F1, direct phosphorylation, and stable physical interaction. We have demonstrated that cisplatin cytotoxicity depends on Cdk2 activity, and Cdk2 inhibition protects kidney cells from cisplatin-induced cell death in vitro and in vivo. Now we show that E2F1 is an important downstream effector of Cdk2 that accumulates in mouse kidneys and in cultured mouse proximal tubular cells (TKPTS) after cisplatin exposure by a Cdk2-dependent mechanism. Direct inhibition of E2F1 by transduction with adenoviruses expressing an E2F1-binding protein (TopBP1) protected TKPTS cells from cisplatin-induced apoptosis, whereas overexpression of E2F1 caused cell death. Moreover, E2F1 knockout mice were markedly protected against cisplatin nephrotoxicity by both functional and histological criteria. Collectively, cisplatin-induced cell death is dependent on Cdk2 activity, which is at least partly through the Cdk2-E2F1 pathway both in vitro and in vivo.

acute kidney injury; cell cycle; cell death

This article has been cited by other articles:

				M. Jiang and Z. Dong Regulation and Pathological Role of p53 in Cisplatin Nephrotoxicity J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 300 - 307. [Abstract] [Full Text] [PDF]

				A. B. Sanz, B. Santamaria, M. Ruiz-Ortega, J. Egido, and A. Ortiz Mechanisms of Renal Apoptosis in Health and Disease J. Am. Soc. Nephrol., September 1, 2008; 19(9): 1634 - 1642. [Abstract] [Full Text] [PDF]

				F. Yu, J. Megyesi, and P. M. Price Cytoplasmic initiation of cisplatin cytotoxicity Am J Physiol Renal Physiol, July 1, 2008; 295(1): F44 - F52. [Abstract] [Full Text] [PDF]

				D. Sheikh-Hamad Cisplatin-induced cytoxicity: is the nucleus relevant? Am J Physiol Renal Physiol, July 1, 2008; 295(1): F42 - F43. [Full Text] [PDF]

				A. Weidemann, W. M. Bernhardt, B. Klanke, C. Daniel, B. Buchholz, V. Campean, K. Amann, C. Warnecke, M. S. Wiesener, K.-U. Eckardt, et al. HIF Activation Protects From Acute Kidney Injury J. Am. Soc. Nephrol., March 1, 2008; 19(3): 486 - 494. [Abstract] [Full Text] [PDF]